Does Meloxicam Make You Sleepy? Side Effects Explained

Meloxicam does not typically cause drowsiness, and sleepiness is not listed among its common side effects in prescribing information. That said, some people do report feeling tired or sluggish while taking it, and the reasons behind that experience are more layered than a simple yes-or-no answer suggests. The drug’s relationship to sleep biology, the conditions it treats, and individual genetic variation all play a role in whether you might feel drowsy on meloxicam.

What the Prescribing Label Actually Says

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) prescribed for pain and inflammation, most often for osteoarthritis and rheumatoid arthritis. Its official prescribing information lists gastrointestinal problems, dizziness, and headache among the more frequently reported side effects. Drowsiness or sedation does not appear in the common or even the uncommon side-effect categories. This distinguishes meloxicam from opioid painkillers and muscle relaxants, which reliably make people sleepy.

That does not mean nobody feels tired on meloxicam. Post-marketing reports and patient forums include occasional complaints of fatigue, and dizziness itself can be mistaken for drowsiness. But when researchers run controlled trials, sedation rarely shows up as a statistically meaningful finding. In one study comparing meloxicam to another NSAID in animals after surgery, there were no significant differences in sedation scores between the two drugs over a 20-hour observation period, and neither drug produced notable sedation on its own.¹ While animal data is not a perfect mirror for humans, it is consistent with the broader clinical picture: meloxicam is not a sedating drug.

Why You Might Still Feel Tired

If meloxicam itself rarely causes sleepiness, why do some people feel wiped out after starting it? The most common explanation has nothing to do with the pill and everything to do with what prompted you to take it. Conditions like rheumatoid arthritis and osteoarthritis are closely tied to fatigue. Research into fatigue in rheumatoid arthritis has found that the symptom can be overwhelming for patients and remains inadequately managed, partly because its causes are complex and shift over time with both disease progression and treatment.² Chronic inflammation triggers signaling molecules that produce a sense of malaise, and poor sleep from ongoing pain only compounds the problem.

When you start an anti-inflammatory and your pain begins to ease, your body may finally relax enough for accumulated fatigue to surface. Think of it like finally sitting down after being on your feet all day: you were exhausted the whole time, but the pain kept you in a state of low-grade alertness. The drug did not cause the tiredness. It removed the distraction that was masking it.

There is also a timing effect. Meloxicam has a half-life of about 20 hours, meaning it stays in your system long enough for once-daily dosing, and roughly 99 percent of the drug is converted to inactive metabolites before being excreted.³ Because it lingers, any subtle effect on how you feel can persist through the day. If taking it in the morning leaves you feeling a bit off, switching to a bedtime dose is a simple adjustment some doctors suggest, though this is more about managing perception than addressing a pharmacological sedation effect.

The Prostaglandin Connection to Sleep

Meloxicam works by blocking cyclooxygenase (COX) enzymes, which reduces the production of prostaglandins. These are the molecules responsible for pain, swelling, and fever. But prostaglandins also play a role in regulating sleep, which is where things get interesting.

Prostaglandin D2 is one of the strongest known sleep-promoting substances in the brain, while prostaglandin E2 tends to promote wakefulness. Because meloxicam preferentially blocks COX-2, it alters the balance of these molecules. A mouse study investigating this pathway found something unexpected: animals given meloxicam before an immune challenge actually showed an increase in non-rapid-eye-movement (NREM) sleep compared to animals that received the immune stimulus alone. The researchers concluded that some COX products may normally act to suppress the sleep-promoting response, and blocking them with meloxicam removed that brake.⁴

This is far from proof that meloxicam makes humans sleepy under normal conditions. The study involved mice experiencing a strong inflammatory stimulus, not people taking a standard dose for a sore knee. But it does suggest a plausible biological pathway through which COX inhibition could nudge sleep architecture in certain circumstances, particularly when inflammation is involved. The effect is context-dependent and subtle, which is consistent with the clinical reality: most people notice nothing, but a few might.

Does Meloxicam Even Reach the Brain?

For any drug to directly cause drowsiness, it generally needs to cross the blood-brain barrier and interact with brain chemistry. Research ranking various NSAIDs by their ability to cross the blood-brain barrier in laboratory models found that transporter proteins are actively involved in moving NSAIDs across this barrier, and that different NSAIDs have meaningfully different transport profiles.⁵ Meloxicam does reach the central nervous system to some degree, which is part of why it can affect pain perception centrally. But the extent of brain penetration is modest compared to more lipophilic drugs that are specifically designed to act in the brain.

This matters because it helps explain why meloxicam is so rarely sedating. Drugs that reliably cause drowsiness, like antihistamines or benzodiazepines, flood the central nervous system and bind to receptors that directly dampen brain activity. Meloxicam does not do that. Its primary action happens in peripheral tissues where inflammation occurs. Whatever central effects it has are secondary and inconsistent from person to person.

Genetic Variation Changes How Much Drug Stays in Your System

One reason two people can have very different experiences on the same dose of meloxicam is genetic. The drug is metabolized primarily by the liver enzyme CYP2C9, and variations in the gene that codes for this enzyme are surprisingly common. A pharmacokinetic study found that steady-state plasma concentrations of meloxicam can vary by roughly 2.4 to 5.4 times depending on a person’s CYP2C9 genotype.⁶ That is a massive range. A person who is a poor metabolizer could have several times more meloxicam circulating in their blood than an extensive metabolizer taking the exact same dose.

Higher drug levels do not automatically translate to drowsiness, but they do increase the likelihood and intensity of any side effect, including the subtle central nervous system effects that some people perceive as tiredness. If you feel unusually sluggish on meloxicam while others tolerate it easily, your CYP2C9 status could be part of the explanation. Pharmacogenomic testing is available but rarely ordered for NSAID prescriptions, since the drug is generally well tolerated and the consequences of being a poor metabolizer are less dangerous than with drugs like warfarin, which is also metabolized by CYP2C9.

When Meloxicam Actually Improves Sleep

Ironically, the most robust finding about meloxicam and sleep is that it can make sleep better, not worse. A double-blind crossover study in women with painful periods compared meloxicam to melatonin and found that both improved subjective sleep quality and reduced pain during menstrual cycles. Objective measures confirmed the improvement: sleep efficiency increased and the time it took to fall asleep shortened in the meloxicam group.⁷ Melatonin outperformed meloxicam on sleep outcomes, which is not surprising given that melatonin is literally a sleep hormone, but the fact that an anti-inflammatory came close underscores how much pain disrupts rest.

This pattern shows up in surgical recovery as well. A randomized clinical trial of intravenous meloxicam after total knee replacement found that patients receiving meloxicam used about 32 percent less opioid medication in the first 24 hours compared to placebo, with the opioid-sparing benefit persisting through 72 hours.⁸ Since opioids are a major cause of postoperative drowsiness and cognitive fog, a drug that lets you take fewer of them indirectly helps you stay more alert during recovery. In that context, meloxicam is an anti-drowsiness tool.

Other Side Effects Worth Knowing About

While drowsiness is not a significant concern with meloxicam, other side effects deserve attention. The gastrointestinal risks are the most well-known. Like all NSAIDs, meloxicam can irritate the stomach lining and increase the risk of ulcers and bleeding, though its COX-2 selectivity gives it a somewhat gentler GI profile compared to older, non-selective NSAIDs like ibuprofen or naproxen. “Somewhat” is the key word: the risk is lower, not absent.

Cardiovascular risk is the other headline concern. All NSAIDs carry a warning about increased risk of heart attack and stroke with prolonged use, and meloxicam is no exception. The risk is dose-dependent and increases with duration, which is why doctors generally recommend using the lowest effective dose for the shortest time needed.

The side effects that are more likely to be confused with drowsiness include:

Dizziness: reported more frequently than fatigue, and easily mistaken for sleepiness, especially when standing up quickly.
Headache: can produce a foggy, low-energy feeling that overlaps with how people describe drowsiness.
Fluid retention: mild swelling and a general sense of heaviness that some people interpret as fatigue.

If you experience genuine, persistent drowsiness on meloxicam, it is worth mentioning to your doctor, not because the drug is dangerous in this regard, but because it may point to something else going on. Unrecognized anemia, thyroid issues, or worsening of the underlying inflammatory condition can all cause fatigue that happens to coincide with starting a new medication.

Kidney and Liver Function, Age, and Dose Adjustments

Pharmacokinetic data on meloxicam show that neither moderate kidney impairment nor moderate liver impairment significantly changes how the drug behaves in the body, and no dose adjustment is needed in older adults based on age alone.⁹ This is reassuring for older patients who are often on multiple medications and more sensitive to drug side effects in general. However, the CYP2C9 genetic variation discussed earlier is an independent factor that has nothing to do with age or organ function. An otherwise healthy 30-year-old who is a poor metabolizer may carry higher drug levels than a 70-year-old who metabolizes the drug normally.

Severe kidney or liver disease is a different story, and most prescribing guidelines recommend caution or avoidance of NSAIDs in that setting. The concern there is less about drowsiness and more about the risk of further organ damage, fluid overload, and bleeding.

Drug Interactions That Can Cause Drowsiness

Meloxicam alone is unlikely to sedate you, but it is rarely taken in isolation. Many people using it for chronic pain are also on medications that do cause drowsiness: muscle relaxants, antidepressants, gabapentin, pregabalin, or low-dose opioids. When someone starts meloxicam and feels sleepy, the culprit is often one of these other drugs, or a combination effect. Adding an NSAID can subtly shift how other medications are metabolized or tolerated, and the resulting drowsiness gets pinned on the newest addition to the regimen.

Alcohol is another common factor. NSAIDs and alcohol are both processed by the liver and both irritate the stomach, so most prescribers advise limiting alcohol while on meloxicam. But the practical reality is that some people continue drinking, and the combination of even moderate alcohol with any NSAID can amplify fatigue and GI discomfort. If you are feeling drowsy on meloxicam and also having a glass of wine with dinner, the wine is the more likely sedative.

Meloxicam in Veterinary Medicine and Why Pet Owners Ask About Drowsiness

A surprising number of searches about meloxicam and sleepiness come from pet owners. Meloxicam is widely prescribed in veterinary medicine for dogs and cats with arthritis or post-surgical pain. Owners notice their pet sleeping more after starting the medication and naturally wonder whether the drug is sedating them. The same logic that applies to humans generally applies to animals: reduced pain leads to more comfortable rest, which can look like sedation. The feline surgery study mentioned earlier found no significant sedation effect from meloxicam compared to another common veterinary NSAID.¹ The increased sleeping is almost certainly the animal finally being comfortable enough to rest normally after days or weeks of pain-interrupted sleep.

Veterinary doses differ substantially from human doses, and formulations designed for pets should never be used interchangeably with human prescriptions. But the pharmacological story is the same: meloxicam reduces inflammation and pain without directly depressing the central nervous system the way a true sedative would.